A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 90
- Population
- ALL · 50 Years
- Duration
- 2013-12-01 to 2015-12-01
- Intervention
- Aflibercept
- Comparator
- Not reported
- Outcomes measured
- Change from baseline in maximal height of pigment epithelium detachment (PED) at 12 weeks — Baseline and 12 weeks; Change from baseline in central retinal thickness by SD OCT at 12 weeks — Baseline and 12 weeks; Change from Baseline in visual acuity at 12 weeks — Baseline and 12 weeks; Change from Baseline in volume of pigment epithelium detachment at 12 weeks — Baseline and 12 weeks; Association with genes involved in AMD history — genetic testing will be performed when all the particpitants will be r…; Number of participants with adverse events from baseline to 32 weeks — from baseline to 32 weeks; Change from Baseline in pigment epithelium detachment height at 12 weeks — Baseline and 12 weeks; Change from baseline in central retinal thickness at 32 weeks — baseline and 32 weeks; Change from Baseline in pigment epithelium detachment height at 32 weeks — Baseline and 32 weeks; Change from Baseline in visual acuity at 32 weeks — Baseline and 32 weeks; Change from Baseline in volume of pigment epithelium detachment at 32 weeks — Baseline and 32 weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 80% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 80%Title contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.